Compare Global X Uranium ETF (URA) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Uranium ETF vs DENTSPLY SIRONA Inc — how do they compare? Global X Uranium ETF trades at $38.79 (market cap $5.48B), while DENTSPLY SIRONA Inc trades at $8.82 (market cap $1.73B). The key difference: Global X Uranium ETF is far larger — about 3.2× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while Global X Uranium ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Uranium ETF for 62 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| URA | XRAY | |
|---|---|---|
Market Cap | $5.48B | $1.73B |
Volume | 5,287,170 | 6,198,582 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $61.81 | $14.68 |
52-Week Low | $37.52 | $8.52 |
Typical Hold Time | 62 Days | 72 Days |
Enterprise Value | — | $3.80B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URA (Global X Uranium ETF) is trading at $38.96, down 2.43% today amid bearish technical signals. The ETF faces selling pressure with 19 sell signals versus 3 buy signals across technical indicators. Recent news highlights nuclear energy's growth potential from AI power demand and government support, though uranium ETFs have experienced volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.
The nuclear sector shows long-term potential driven by AI energy demands and government investments, but URA faces near-term technical headwinds. Key risks include commodity price volatility and concentrated holdings. Analyst sentiment remains mixed with some seeing value after recent declines while others caution about sector-specific challenges.
DENTSPLY SIRONA (XRAY) trades at $8.83, down 3.4% with bearish technical signals. The stock faces fundamental challenges with negative net income margins (-14.99%) and declining revenue trends ($3.68B in 2025). Recent Q2 2026 earnings beat expectations but sales fell 4.1% amid ongoing turnaround efforts. The company maintains strong institutional interest despite hitting 52-week lows in September 2026.
XRAY presents a high-risk opportunity with Wall Street maintaining a cautious stance (37.5% buy rating). The consensus price target of $13.40 offers 52% upside potential, but investors face execution risks in the dental equipment turnaround, margin pressures, and competitive challenges. Near-term catalysts include management's presentation at the Baird Healthcare Conference in September 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
